acute lymphoblastic leukaemia Archives -

Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus

Blackstone revs up Autolus’ CAR with $250m fuel injection

https://pharmaphorum.com/news/blackstone-revs-up-autolus-car-with-250m-fuel-injection/

Kite claims a first for CAR-T Tecartus in adult leukaemia

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor

Kite claims a first for CAR-T Tecartus in adult leukaemia

https://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/

News/ News/ Oncology

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

Phil Taylor acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus 0 Comment

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/

News/ News/ News/ Oncology/ Patients

Real-world data backs Kymriah’s safety profile, says Novartis

Phil Taylor acute lymphoblastic leukaemia, Haematology, Kymriah, Non-Hodgkins Lymphoma, Novartis, real world data 0 Comment

With more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

News/ News/ Oncology

Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO

Richard Staines acute lymphoblastic leukaemia, blood cancer, cancer, CAR T, non-Hodgkin lymphoma, R&D 0 Comment

It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership

Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO

https://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/

News/ News/ Oncology/ Top stories

Amgen’s blood cancer drug gets full EU licence

Richard Staines acute lymphoblastic leukaemia, Amgen, blood cancer 0 Comment

FDA granted full licence last year

Amgen’s blood cancer drug gets full EU licence

https://pharmaphorum.com/news/amgens-blood-cancer-drug-blincyto-licence/

Cancer/ Market Access/ News/ News/ News/ News/ Oncology/ Pharma Market Access/ R&D/ UK & Europe

NICE to reassess Pfizer blood cancer drug

Richard Staines acute lymphoblastic leukaemia, blood cancer, market access, NICE, Pfizer 0 Comment

Company successfully appealed against rejection last summer

NICE to reassess Pfizer blood cancer drug

https://pharmaphorum.com/news/nice-reassess-pfizer-blood-cancer-drug/

News/ US

Novartis close to first-ever CAR-T approval after unanimous vote

Richard Staines acute lymphoblastic leukaemia, blood cancer, cancer, CAR T, cell and gene therapy, fda, Kite Pharma, Novartis 0 Comment

Panel unanimously back CTL019

Novartis close to first-ever CAR-T approval after unanimous vote

https://pharmaphorum.com/news/novartis-car-t-ctl019-backed-fda-advisers/

News/ UK & Europe

Pfizer facing NICE showdown over leukaemia drug

Richard Staines acute lymphoblastic leukaemia, blood cancer, cancer, NICE, Pfizer 0 Comment

Pfizer locks horns with NICE following EU approval.

Pfizer facing NICE showdown over leukaemia drug

https://pharmaphorum.com/news/pfizer-facing-nice-showdown-drug/

Trending

acute lymphoblastic leukaemia

Login